Filing Flows › Allogene Therapeutics (ALLO) › Guidance & outlook
Allogene Therapeutics (ALLO) guidance and outlook
Allogene Therapeutics (ALLO) reaffirmed its guidance on Nov 5, 2026: Operating expenses $225M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Operating expenses | FY2026 | $225M | reaffirmed |
| Stock-based compensation | FY2026 | $35.0M | new |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Allogene Therapeutics' latest quarter
Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Allogene Therapeutics raise or lower its guidance?
Allogene Therapeutics (ALLO) reaffirmed its guidance on Nov 5, 2026: Operating expenses $225M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.